Inconsistencies in cardiovascular data from COX-2 inhibitor trials - Is it a class effect?

Journal of the Royal Society of Medicine

Volumn 99, Issue 6, 2006, Pages 275-276

  Weatherall, Mark ^a   Aldington, Sarah ^b   Caldwell, Brent ^b   Beasley, Richard ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DEATH; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; INCIDENCE; MEDICAL PERSONNEL; MEDICAL RESEARCH; MORTALITY; PUBLIC HEALTH SERVICE; PUBLICATION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33745758093     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.99.6.275     Document Type: Editorial

References (11)

1. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis". N Engl J Med 2000;343:1520-8;
2. Curfman GD, Morrissey S, Drazen JM. N Engl J Med 2005;353:2813
3. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. [http://content.nejm.org/cgi/content/abstract/NEJMe068054]
4. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and metaanalysis. J R Soc Med 2006;99:132-40
5. Silverstein FE, Faich G, Goldestein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55
6. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30
7. Witter J. Celebrex capsules (celecoxib). NDA 20-998/S-009. Medical Officer Review. US Department of Health and Human Services Food and Drug Administration, 2000 [http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3677b1_03_med.pdf]
8. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002;324:1287-8
9. Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [Letter]. JAMA 2001;286:2398-9
10. Berg Hrachovec J, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [letter]. JAMA 2001;286:2398
11. Celecoxib and the CLASS trial: data massaging by industry. Prescribe Int 2002;11:190-1